• Je něco špatně v tomto záznamu ?

30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985 - 2016/17

R. Cífková, J. Bruthans, P. Wohlfahrt, A. Krajčoviechová, P. Šulc, M. Jozífová, L. Eremiášová, J. Pudil, A. Linhart, J. Widimský, J. Filipovský, O. Mayer, Z. Škodová, R. Poledne, P. Stávek, V. Lánská,

. 2020 ; 15 (5) : e0232845. [pub] 20200511

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025018

Grantová podpora
NV15-27109A MZ0 CEP - Centrální evidence projektů

BACKGROUND: Compared with Western Europe, the decline in cardiovascular (CV) mortality has been delayed in former communist countries in Europe, including the Czech Republic. We have assessed longitudinal trends in major CV risk factors in the Czech Republic from 1985 to 2016/17, covering the transition from the totalitarian regime to democracy. METHODS: There were 7 independent cross-sectional surveys for major CV risk factors conducted in the Czech Republic in the same 6 country districts within the WHO MONICA Project (1985, 1988, 1992) and the Czech post-MONICA study (1997/98, 2000/01, 2007/08 and 2016/2017), including a total of 7,606 males and 8,050 females. The population samples were randomly selected (1%, aged 25-64 years). RESULTS: Over the period of 31/32 years, there was a significant decrease in the prevalence of smoking in males (from 45.0% to 23.9%; p < 0.001) and no change in females. BMI increased only in males. Systolic and diastolic blood pressure decreased significantly in both genders, while the prevalence of hypertension declined only in females. Awareness of hypertension, the proportion of individuals treated by antihypertensive drugs and consequently hypertension control improved in both genders. A substantial decrease in total cholesterol was seen in both sexes (males: from 6.21 ± 1.29 to 5.30 ± 1.05 mmol/L; p < 0.001; females: from 6.18 ± 1.26 to 5.31 ± 1.00 mmol/L; p < 0.001). CONCLUSIONS: The significant improvement in most CV risk factors between 1985 and 2016/17 substantially contributed to the remarkable decrease in CV mortality in the Czech Republic.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025018
003      
CZ-PrNML
005      
20201222155013.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0232845 $2 doi
035    __
$a (PubMed)32392239
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cífková, Renata $u Center for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University in Prague, Prague, Czech Republic. Department of Medicine II, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
245    10
$a 30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985 - 2016/17 / $c R. Cífková, J. Bruthans, P. Wohlfahrt, A. Krajčoviechová, P. Šulc, M. Jozífová, L. Eremiášová, J. Pudil, A. Linhart, J. Widimský, J. Filipovský, O. Mayer, Z. Škodová, R. Poledne, P. Stávek, V. Lánská,
520    9_
$a BACKGROUND: Compared with Western Europe, the decline in cardiovascular (CV) mortality has been delayed in former communist countries in Europe, including the Czech Republic. We have assessed longitudinal trends in major CV risk factors in the Czech Republic from 1985 to 2016/17, covering the transition from the totalitarian regime to democracy. METHODS: There were 7 independent cross-sectional surveys for major CV risk factors conducted in the Czech Republic in the same 6 country districts within the WHO MONICA Project (1985, 1988, 1992) and the Czech post-MONICA study (1997/98, 2000/01, 2007/08 and 2016/2017), including a total of 7,606 males and 8,050 females. The population samples were randomly selected (1%, aged 25-64 years). RESULTS: Over the period of 31/32 years, there was a significant decrease in the prevalence of smoking in males (from 45.0% to 23.9%; p < 0.001) and no change in females. BMI increased only in males. Systolic and diastolic blood pressure decreased significantly in both genders, while the prevalence of hypertension declined only in females. Awareness of hypertension, the proportion of individuals treated by antihypertensive drugs and consequently hypertension control improved in both genders. A substantial decrease in total cholesterol was seen in both sexes (males: from 6.21 ± 1.29 to 5.30 ± 1.05 mmol/L; p < 0.001; females: from 6.18 ± 1.26 to 5.31 ± 1.00 mmol/L; p < 0.001). CONCLUSIONS: The significant improvement in most CV risk factors between 1985 and 2016/17 substantially contributed to the remarkable decrease in CV mortality in the Czech Republic.
650    _2
$a dospělí $7 D000328
650    _2
$a antihypertenziva $x terapeutické užití $7 D000959
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a kardiovaskulární nemoci $x epidemiologie $x etiologie $7 D002318
650    _2
$a kouření cigaret $x epidemiologie $7 D000073865
650    _2
$a průřezové studie $7 D003430
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdraví - znalosti, postoje, praxe $7 D007722
650    _2
$a zdravotnické přehledy $7 D006306
650    _2
$a lidé $7 D006801
650    _2
$a hypercholesterolemie $x epidemiologie $7 D006937
650    _2
$a hypertenze $x farmakoterapie $x epidemiologie $7 D006973
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a morbidita $x trendy $7 D009017
650    _2
$a mortalita $x trendy $7 D009026
650    _2
$a obezita $x epidemiologie $7 D009765
650    _2
$a politika $7 D011057
650    _2
$a rizikové faktory $7 D012307
650    _2
$a sociální změna $7 D012922
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bruthans, Jan $u Center for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Wohlfahrt, Peter $u Center for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Krajčoviechová, Alena $u Center for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Šulc, Pavel $u Center for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Jozífová, Marie $u Center for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Eremiášová, Lenka $u Department of Medicine II, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Pudil, Jan $u Department of Medicine II, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Linhart, Aleš $u Department of Medicine II, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Widimský, Jiří $u Department of Medicine III, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Filipovský, Jan $u Department of Medicine II, Faculty of Medicine, Charles University, Pilsen, Czech Republic.
700    1_
$a Mayer, Otto $u Department of Medicine II, Faculty of Medicine, Charles University, Pilsen, Czech Republic.
700    1_
$a Škodová, Zdenka $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Poledne, Rudolf $u Atherosclerosis Research Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Stávek, Petr $u Atherosclerosis Research Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Lánská, Věra $u Medical Statistics Unit, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 15, č. 5 (2020), s. e0232845
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32392239 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155009 $b ABA008
999    __
$a ok $b bmc $g 1599163 $s 1115704
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 15 $c 5 $d e0232845 $e 20200511 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NV15-27109A $p MZ0
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace